Evidence map›Paper›PMID 33068444›Full record

Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2021

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.

C Bodemer, A Kaszuba, K Kingo, A Tsianakas, A Morita, E Rivas, P Papanastasiou, D Keefe, M Patekar, P Charef and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02471144 (A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept), which is not on this map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02471144 phase3completednot on this map

A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2015 to 2023Enrolled162ConditionsChronic Severe Plaque-type PsoriasisArmsExperimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Psoriasis.Nature reviews. Disease primers · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 8 countries.

C BodemerDepartment of Dermatology, Hôpital Necker-Enfants Malades, APHP, Paris, France.
A KaszubaDERMED Medical Services, Lodz, Poland.
K KingoTartu University Hospital and University of Tartu, Tartu, Estonia.
A TsianakasFachklinik Bad Bentheim, Bad Bentheim, Germany.
A MoritaNagoya City University Hospital, Aichi, Japan.
E RivasDermos, Guatemala City, Guatemala.
P PapanastasiouNovartis Pharma AG, Basel, Switzerland.
D KeefeNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
M PatekarNovartis Pharma AG, Basel, Switzerland.
P CharefNovartis Pharma AG, Basel, Switzerland.
L ZhangNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
S CafoncelliNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
C PapavassilisNovartis Pharma AG, Basel, Switzerland.
Novartis (Switzerland) · CHNovartis (United States) · USAssistance Publique – Hôpitaux de Paris · FRChristoffel Blinden Mission · DEHospital General San Juan de Dios · GTMedical University of Lodz · PLNagoya City University Hospital · JPUniversity of Tartu · EE

Funding

Novartis Pharma AG
6 · The paper itself

Abstract

backgroundSecukinumab has demonstrated sustained long-term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults.

objectivesHere, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported.

methodsIn this multicentre, double-blind study (NCT02471144), patients aged 6 to <18 years with severe chronic plaque psoriasis were stratified and randomized by weight (<25 kg, 25 to <50 kg, ≥50 kg) and age (6 to <12 years, 12 to <18 years) to receive low-dose (LD: 75/75/150 mg) or high-dose (HD: 75/150/300 mg) subcutaneous secukinumab or placebo or etanercept 0.8 mg/kg (up to a max of 50 mg).

resultsOverall, 162 patients were randomized to receive secukinumab LD (n = 40) or HD (n = 40), etanercept (n = 41) or placebo (n = 41). The co-primary objectives of the study were met with both secukinumab doses (LD and HD) showing superior efficacy compared to placebo (P < 0.0001) with respect to PASI 75 response (80.0%, 77.5% vs. 14.6%) and IGA mod 2011, 0 or 1 response (70%, 60% vs. 4.9%) at Week 12. Both secukinumab doses were superior to placebo (P < 0.0001) with respect to PASI 90 response at Week 12 (72.5%, 67.5% vs. 2.4%). The efficacy of both doses was sustained to Week 52 with secukinumab achieving higher responses vs. etanercept (PASI 75/90/100: LD, 87.5%/75.0%/40.0% and HD, 87.5%/80.0%/47.5.% vs. etanercept, 68.3%/51.2%/22.0% and IGA 0 or 1: LD, 72.5% and HD, 75.0% vs. etanercept, 56.1%). The safety profile of secukinumab was consistent with the adult Phase 3 studies, with no new safety signals identified.

conclusionsBoth doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.

Indexed as

Antibodies, MonoclonalPsoriasisAdultAntibodies, Monoclonal, HumanizedChildDouble-Blind MethodHumansSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, Humanizedsecukinumab

Identifiers

PMID33068444
PMCPMC7986088
OpenAlexW3092915044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.